Cannabis Testing

Since 2018 Brightlabs possesses an opium exemption from the BMC (Bureau for Medicinal Cannabis), for the analysis of cannabis and related products. The combination of this opium exemption, combined with our GMP accreditation, makes Brightlabs an important partner for the analysis of cannabis and related materials for the Pharmaceutical industry, research institutes and supplements sector. Starting in 2023 Brightlabs is analyzing the cannabis and hashish for the Dutch closed coffeeshop chain.

Every year Brightlabs receives thousands of cannabis samples for the analysis of cannabinoids, terpenes or unwanted pollutants like heavy metals or microbiological burden.

By now Brightlabs has ample experience with the analysis of a wide range of products such as CBD-oil and candy, as the analysis of pharmaceutical products, ranging from hand sanitizer to medicinal cannabis in conformity with the current Pharmacopoeia.

For this experiment Brightlabs has setup all needed analyses in-house specifically for the requirements as needed for the Experiment closed coffeeshop chain.

With the Experiment closed coffeeshop chain the government is investigating the possibility to provide the Dutch coffeeshops with legal produced cannabis. In a period of 4 year 10 breeders are allowed to produce cannabis legally. For more information see the website below:

Part of this experiment is about the quality of the cannabis products, one part is that the packaging should clearly show the amount of THC and CBD present in the product. Secondly the products should be free of pollutant like heavy metals and microbiological burden, and free of and toxins like aflatoxins. Brightlabs offers a full range of analysis to cover all the requirements, which covers at least:

  • Cannabinoids, (THCA, CBDA, THC, CBD, total THC-equivalent and total CBD-equivalent)
  • Heavy Metals, (Lead, Cadmium, Mercury and Arsenic)
  • Alfatoxines, (Sum of B1, B2, G1 and G2)
  • Microbiological burden, (TAMC, TYMA and S. Aureus)

Furthermore we also offer other analysis:

  • Full Screen Cannabinoids (up to 17 different cannabinoids)
  • Terpenes
  • Pesticides
  • Dry Weight (Loss on Drying)
  • Additional Microbiological analysis

Not all our capabilities are mentioned online, and are continues being updated and expended. Feel free to contact us about to discuss the possibilities.

Besides out opiate permit, Brightlabs also is in the possession of a GMP license, which enable us to perform analysis on medicinal cannabis for the final product release under GMP.

We can perform analysis under GMP on plant material, but also other cannabis related products like pure isolates (i.e. THC (Dronabinol) and CBD (Cannabidiol), or formulated drug products like tablets and injectables. We work in accordance to different pharmacopeial and German DAB/DAC monographs.

  • Identification, using TLC (2.2.27) and Microscopic examination (2.8.23)
  • Loss on Drying (2.2.32)
  • Foreign Material
  • Aflatoxines (2.8.18)
  • Pesticides (2.8.13)
  • Heavy Metals (2.4.27)(2.2.58)
  • Assay and Related Substances (2.2.29)
  • Microbial contamination (2.6.12)(2.6.13):

Brightlabs has an in-house method with which different cannabinoids can be quantitatively analysed. This method makes it possible to quantify the level of d9-THC, to verify whether all legislation is met. Furthermore, we have our own GC-MS method for the analysis of terpenes.

Aside from the desired products (CBD & Terpenes), Brightlabs has a wide scale of analysis possibilities to check your product for the presence of unwanted components, such as:

  • Heavy metals
  • Mycotoxins (B1, B2, G1 & G2)
  • Residual Pesticides
  • Residual Solvents
  • Micro biological contaminations

Plant material can be subjected to a wide scale of analyses, both for the testing in conformity with current GMP monographs as for research purposes.

For this purpose, various analyses can be performed, for example:

  • Cannabinoids (Assay or screen)
  • Terpenes
  • Identity and contaminations
  • Loss on Drying (LOD)
  • Mycotoxins (B1, B2, G1 & G2)
  • Residual Pesticides
  • Micro Biological contaminations

Since 2020 Brightlabs performs the analysis for medicinal cannabis for the BMC, as part of the exemption conform to the Dutch monograph.


Questions? Please feel free to contact us.

Curious what Brightlabs can do for you?

Download our brochure